Apellis Pharmaceuticals’ Phase 3 Study on Pegcetacoplan: A Potential Game-Changer in AMD Treatment

Apellis Pharmaceuticals ((APLS)) announced an update on their ongoing clinical study.

Apellis Pharmaceuticals is conducting a Phase 3 extension study titled A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration. The study aims to assess the long-term safety and efficacy of pegcetacoplan in patients with geographic atrophy due to age-related macular degeneration, following their participation in previous related studies.

The intervention being tested is pegcetacoplan (APL-2), a complement (C3) inhibitor administered intravitreally. It is designed to slow the progression of geographic atrophy, a severe form of age-related macular degeneration.

This interventional study is non-randomized with a parallel assignment model. It is open-label, meaning no masking is involved, and its primary purpose is treatment. Participants receive pegcetacoplan either monthly or every other month for up to 36 months.

The study began on March 4, 2021, with an estimated completion date in 2025. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might impact the market.

The ongoing study could significantly influence Apellis Pharmaceuticals’ stock performance and investor sentiment, especially if the results demonstrate positive long-term safety and efficacy. This could also affect competitors in the age-related macular degeneration treatment market.

The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.